ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Burden of Treatment for Adult and Adolescent People with Haemophilia (PwH): Concept Elicitation Results Supporting the Development of the Hemophilia Treatment Experience Measure (Hemo-TEM)

M. Brod1, L. Waldman2, J. Skov Neergaard3, A. Busk3

1The Brod Group, Mill Valley, California, United States, 2The Brod Group, San Diego, California, United States, 3Novo Nordisk A/S, Søborg, Hovedstaden, Denmark

Abstract Number: PB0654

Meeting: ISTH 2022 Congress

Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical

Background: Currently available treatments for PwH have resulted in significant improvements in quality of life. However, PwH may still experience considerable treatment burden due to technical, physical, logistical, and emotional aspects of self-administering intravenous infusions. Most research to date has focused on disease burden rather than treatment burden.

Aims: This study’s purpose was to investigate treatment burden among adult and adolescent PwH and collect data to support the content validity of a new disease-specific patient-reported outcome measure of treatment burden.

Methods: Following U.S. Food and Drug Administration guidelines, interviews were conducted with 30 adult males with moderate or severe haemophilia, with or without inhibitors, and who self-infused prophylactically or on demand. Interviews were analysed and coded using an adapted grounded theory approach to determine overarching themes and concepts. A theoretical model of treatment burden was then developed, and items for the new Hemo-TEM measure were generated and cognitively debriefed in a total of 35 PwH (15 adults and 20 adolescents).

Results: Qualitative analysis revealed that saturation of concepts was reached with 5 treatment burden domains: injection difficulties; adherence; emotional burden; physical burden; and interference with daily life. Sub-concepts endorsed by patients included inserting the needle correctly (53%) and fitting treatment into daily schedule (43%) (injection difficulties); missed (53%) and delayed (40%) treatments (adherence); worry (47%) and anxiety/nervousness (27%) (emotional burden); blown veins (50%) and pain (50%) (physical burden); and travel (73%) and work (40%) (interference with daily life) (Table 1). The cognitive debriefing resulted in a draft measure of 30 items, which were found to be understandable and relevant.

Conclusion(s): The content validity of the Hemo-TEM is supported by these qualitative findings. The validation-ready Hemo-TEM version contained items on treatment difficulties, adherence, emotional burden, physical burden, and interference with daily life and was found acceptable by adult and adolescent patients.

Table

Table 1: Top Sub-concepts by Hemo-TEM Domain

To cite this abstract in AMA style:

Brod M, Waldman L, Skov Neergaard J, Busk A. Burden of Treatment for Adult and Adolescent People with Haemophilia (PwH): Concept Elicitation Results Supporting the Development of the Hemophilia Treatment Experience Measure (Hemo-TEM) [abstract]. https://abstracts.isth.org/abstract/burden-of-treatment-for-adult-and-adolescent-people-with-haemophilia-pwh-concept-elicitation-results-supporting-the-development-of-the-hemophilia-treatment-experience-measure-hemo-tem/. Accessed November 30, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/burden-of-treatment-for-adult-and-adolescent-people-with-haemophilia-pwh-concept-elicitation-results-supporting-the-development-of-the-hemophilia-treatment-experience-measure-hemo-tem/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley